Reuters logo
BRIEF-Insurance unit of Hubei Biocause Pharma posts Jan-Nov premium income at 44.7 bln yuan
December 8, 2017 / 9:28 AM / 6 days ago

BRIEF-Insurance unit of Hubei Biocause Pharma posts Jan-Nov premium income at 44.7 bln yuan

Dec 8 (Reuters) - Hubei Biocause Pharmaceutical Co Ltd :

* SAYS ITS INSURANCE UNIT'S PREMIUM INCOME IN JAN-NOV TOTALLING 44.7 BILLION YUAN ($6.76 billion) Source text in Chinese: bit.ly/2iGRoyc Further company coverage: ($1 = 6.6163 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below